We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Smart Pills Offer Diagnostic Tool for Gut Disorders

By LabMedica International staff writers
Posted on 08 May 2017
Researchers have completed successful phase-one human clinical trials of ingestible capsules (the size of a vitamin pill) that have potential to revolutionize diagnosis and prevention of gastrointestinal (GI) disorders and diseases.

Researchers at RMIT University (Melbourne, Australia), led by the pills’ co-inventor Prof. More...
Kourosh Kalantar-zadeh, tested the ingestible smart capsules that journey through and measure gas levels in the GI tract. The human trials were undertaken with colleagues from Monash University. “We have been lucky to have Monash medical academics helping us on this journey,” said Prof. Kalantar-zadeh, “Without their input we would not be able to proceed.”

RMIT is one of the leading universities researching the development of ingestible sensors, a technology that has demonstrated several 1000s-times more sensitivity to gut gases than current alternative techniques. “Currently, one of the only methods for diagnosing gut disorders, such as mal-absorption of carbohydrates, irritable bowel syndrome, and inflammable bowel disease, is to measure hydrogen concentrations in the breath,” said Prof. Kalantar-zadeh, “However, breath tests are mired by a lack of sensitivity and specificity and are unable to provide the necessary gold standard for diagnosis.”

Co-inventor Dr. Kyle Berean said, “Ingestible sensors also offer a reliable diagnostic tool for colon cancer, meaning that people won’t have to undergo colonoscopies in future.”

A key finding from the initial trials was on the safety of the new technology: “Smart pills are harmless and there is no risk of capsule retention,” said Dr. Berean. An added advantage is that the capsules can be synched with smartphones, meaning results are easily accessible by users and doctors online. There are also many potential applications for this technology.

“The sensors allow us to measure all the fluids and gases in the gut, giving us a multidimensional picture of the human body,” said Prof. Kalantar-zadeh, “Gas sensing is just the beginning.”

A paper by the Centre for Advanced Electronics and Sensors (CADES) research team outlining the future of ingestible sensors was published in the April 2017 issue of the journal ACS Sensors. Outcomes of the human trials were presented at Digestive Disease Week (DDW; Chicago, IL, USA, May 6-9, 2017).


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Microscope
dIFine
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.